<code id='3688AFFA71'></code><style id='3688AFFA71'></style>
    • <acronym id='3688AFFA71'></acronym>
      <center id='3688AFFA71'><center id='3688AFFA71'><tfoot id='3688AFFA71'></tfoot></center><abbr id='3688AFFA71'><dir id='3688AFFA71'><tfoot id='3688AFFA71'></tfoot><noframes id='3688AFFA71'>

    • <optgroup id='3688AFFA71'><strike id='3688AFFA71'><sup id='3688AFFA71'></sup></strike><code id='3688AFFA71'></code></optgroup>
        1. <b id='3688AFFA71'><label id='3688AFFA71'><select id='3688AFFA71'><dt id='3688AFFA71'><span id='3688AFFA71'></span></dt></select></label></b><u id='3688AFFA71'></u>
          <i id='3688AFFA71'><strike id='3688AFFA71'><tt id='3688AFFA71'><pre id='3688AFFA71'></pre></tt></strike></i>

          knowledge

          knowledge

          author:focus    Page View:918
          The logo of Department of Justice on a podium — coverage from STAT
          BRENDAN SMIALOWSKI/AFP via Getty Images

          Community Health Systems is facing a new federal probe into its hospital billing practices more than four years after the hospital chain settled separate allegations of fraudulent overbilling.

          CHS, a national system of 71 rural and suburban hospitals, said this week it received a civil investigative demand from the Department of Justice on Jan. 11. Federal investigators asked CHS to hand over documents that covered “practices and procedures related to utilization review, inpatient admissions, and inpatient dialysis at our hospitals.”

          advertisement

          The DOJ initiates these investigations into health care companies when it believes there could be a False Claims Act case, but has not initiated or joined any lawsuits yet.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs
          Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

          LongtimeBluebirdBioCEONickLeschlyWendyMaeda/TheBostonGlobeSometwoyearsaftersplittingbiotechcompanyBl

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

          CytokineticsCEORobertBlumspokelastweekatatalkduringSTAT’sBreakthroughSummitWestinSanFrancisco.SarahG